Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT04131322
Other study ID # AMGEVITA-HVM2019
Secondary ID
Status Terminated
Phase Phase 4
First received
Last updated
Start date October 10, 2019
Est. completion date June 8, 2020

Study information

Verified date January 2021
Source Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Loss of response of the Adalimumab biosimilar compared with the original drug.


Description:

A single-site Unicentric, randomized, parallel-group, non-inferiority open study including patients diagnosed with inflammatory bowel disease (Crohn's disease and Ulcerative Colitis) who were in clinical remission with Adalimumab original for at least 6 months prior to the start of the study. A total of 216 patients with inflammatory bowel disease from the Inflammatory Unit of the Virgin Macarena University Hospital will be randomized 1:1 to receive the study drug, Adalimumab biosimilar (AMGEVITA®) subcutaneous 40mg every 15 days or maintain the original drug (Humira®) 40 mg subcutaneous every 15 days. The dosage of the medication will be administrated according to the product's approved label by SmPC (Summary of Product's Characteristics)by technical file. Administration will be accepted every 7 days, if the patient after inclusion criteria is included with intensified dose.


Recruitment information / eligibility

Status Terminated
Enrollment 24
Est. completion date June 8, 2020
Est. primary completion date June 8, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Be male or female over 18 years of age - Be a Patient with a previous confirmed diagnosis of Crohn´s disease an Ulcerative Colitis - Previous treated with original Adalimumab for at least 6 months with regular maintenance dose (40 mg every 15 days) and in clinical and biological remission. - Patients under treatment with intensified Adalimumab (40mg every 7 days or 80mg every 7 days) to maintain clinical and biological remission for at least 6 months. - Patients with oral mesalazine with a stable dose for more than 30 days. - Patients with immunosuppressive therapy (methotrexate, azathioprine) with a minimum intake time> 60 days. - Patients may be accepted with corticosteroids at the established doses: prednisone <20mg / dl, budesonide <9mg / dl. - Patients who have a tuberculosis (TB) study (Mantoux / QuantiFERONTB test) updated in the last two year, with a negative result. - Patient with serology hepatitis B and C, updated at the beginning of the treatment with Humira® - Sign an informed consent document indicating that he/she understands the purpose of, and procedures required for, the study and are willing to participate in the study. Exclusion Criteria: - Positive pregnancy test at the time of inclusion or during the follow-up period, as well as women who are breastfeeding - Patients with uncontrolled comorbidities, active cancer, diabetes mellitus, severe cardiovascular disease, obstructive pulmonary disease, serious active infections. - Patients with oral mesalazine initiated less than 30 days. - Patients with immunosuppressive therapy (methotrexate, azathioprine) with a minimum intake time of <60 days. - Patient with original Adalimumab who do not meet a minimum of 6 months of stable dose (40 mg every 7 or 15 days) - Patient on corticosteroid therapy at doses: prednisone> 20mg / dl, budesonide = 9mg / dl, or with IV corticoids within 14 days prior screening date. - Patients with mental disorders, alcohol / other substance abuse, or conditions that do not allow adherence to the study protocol. - Patients with active TB - Patients with defined Hepatitis B and C defined as: HBV: hepatitis B surface antigen (HbsAg) positive together with positive HBV deoxyribonucleic acid (DNA) polymerase chain reaction (PCR). HCV: HCV ribonucleic acid (RNA) detectable in any patient with positive anti-HCV antibody (IgG)

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Amgevita 40Mg Solution for Injection
Adalimumab 40Mg Solution for Injection
HUMIRA 40Mg Solution for Injection
Adalimumab 40Mg Solution for Injection

Locations

Country Name City State
Spain Hospital Universitario Virgen Macarena Sevilla

Sponsors (1)

Lead Sponsor Collaborator
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla

Country where clinical trial is conducted

Spain, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change from baseline to final follow-up in the response of the switch. To assess if there is a change in the response of the switch (replacement) from Adalimumab original (Humira®) to Adalimumab biosimilar (Amgevita®) trhough the quantification of concomitant steroids needed or increment in dose or frequency of adalimumab biosimilar or urgent surgery indication From date of randomization until the date of first documented change from baseline status in concomitant steroids needed or increment in dose or frequency of adalimumab biosimilar or urgent surgery indication ever came first, assessed up to 13 months
Secondary Compare the antibody formation rate. Compare the antibody formation rate with Adalimumab(immunogenicity) after the switch. 0, 3, 6, 9, 12, 13 months
Secondary The score of the specific quality of life questionnaire Compare the score of the specific quality of life questionnaire Short Inflammatory Bowel Disease Questionnaire (SIBDQ) in patients with inflammatory bowel disease before and after the switch.The minimum value is 1 and the maximum is 7, where higher scores means better outcome. 0, 3, 6, 9, 12, 13 months
Secondary The score of the Visual Analogue Scale (VAS) Compare the score of the Visual Analogue Scale (VAS) of pain at the puncture site after the switch. The minimum value is 0 mm and the maximum value is 100 mm, where the higher score means a worse outcome. 0, 3, 6, 9, 12, 13 months
Secondary Maintenance of bioquimical remission trhough C-reactive protein levels of C-reactive protein in blood (mg/L). 0, 3, 6, 9, 12, 13 months
Secondary Maintenance of bioquimical remission through Calprotectin values levels of Calprotectin in blood (µg/g). 0, 3, 6, 9, 12, 13 months
Secondary Drug levels Determination of drug levels in blood (µg/ml). 0, 3, 6, 9, 12, 13 months
Secondary Adverse Event Proportion of patients who experience AE in each treatment group 0, 3, 6, 9, 12, 13 months
Secondary Hospital admission rate Proportion of patients requiring hospital admissions related to a disease outbreak during follow-up. 0, 3, 6, 9, 12, 13 months
Secondary Surgery rate Proportion of patients requiring surgery related to disease activity during follow-up. 0, 3, 6, 9, 12, 13 months
See also
  Status Clinical Trial Phase
Recruiting NCT05702879 - Combined Microbiota and Metabolic Signature in Ulcerative Colitis Predicts Anti-Inflammatory Therapy Success
Not yet recruiting NCT05953402 - A Study of Ozanimod in Pregnant Women With Ulcerative Colitis and Their Offspring
Recruiting NCT05316584 - A Novel Remote Patient and Medication Monitoring Solution to Improve Adherence and PerSiStence With IBD Therapy N/A
Recruiting NCT03950232 - An Extension Study for Treatment of Moderately to Severely Active Ulcerative Colitis Phase 3
Completed NCT03124121 - Study of the Golimumab Exposure-Response Relationship Using Serum Trough Levels Phase 4
Not yet recruiting NCT06100289 - A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease Phase 3
Withdrawn NCT04209556 - A Study To Evaluate The Safety And Efficacy Of PF-06826647 In Participants With Moderate To Severe Ulcerative Colitis Phase 2
Terminated NCT00061282 - Clotrimazole Enemas for Pouchitis in Children and Adults Phase 1/Phase 2
Recruiting NCT04398550 - SCD vs. Mediterranean Diet Therapy in Ulcerative Colitis N/A
Recruiting NCT04314375 - Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Budesonide Extended-release Tablets in Pediatric Subjects Aged 5 to 17 Years With Active, Mild to Moderate Ulcerative Colitis Phase 4
Active, not recruiting NCT04857112 - Study Evaluating Efficacy and Safety of Amiselimod (MT-1303) in Mild to Moderate Ulcerative Colitis Phase 2
Completed NCT05051943 - A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response
Active, not recruiting NCT04033445 - A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis Phase 2/Phase 3
Recruiting NCT05428345 - A Study of Vedolizumab SC Given to Adults With Moderate to Severe Ulcerative Colitis or Crohn's Disease in South Korea
Active, not recruiting NCT06221995 - Energy Expenditure in Patients With Ulcerative Colitis Undergoing Surgery
Recruiting NCT04767984 - Testing Atorvastatin to Lower Colon Cancer Risk in Longstanding Ulcerative Colitis Phase 2
Completed NCT02508012 - Medico-economic Evaluation of the Therapeutic Drug Monitoring of Anti-TNF-α Agents in Inflammatory Bowel Diseases N/A
Recruiting NCT06071312 - FMT in Patients With Recurrent CDI and Ulcerative Colitis: Single Infusion Versus Sequential Approach Phase 1/Phase 2
Completed NCT03760003 - Dose-Ranging Phase 2b Study of ABX464 in Moderate to Severe Ulcerative Colitis Phase 2
Not yet recruiting NCT05539625 - Mini-MARVEL - Mitochondrial Antioxidant Therapy in Ulcerative Colitis Phase 2